Enrolling
CTN 338: PLATINUM-CAN
Placebo-controlled randomized trial of tecovirimat in non-hospitalized patients with Mpox: Canadian Feasibility Study
Learn MoreEnrolling
Placebo-controlled randomized trial of tecovirimat in non-hospitalized patients with Mpox: Canadian Feasibility Study
Learn MoreOngoing
A learning health system to improve care in people living with HIV
Learn MoreOngoing
Perception of menopausal hormone therapy amongst women living with HIV: A feasibility study for a future randomized controlled trial
Learn MoreEnrolling
Enrolling
Longitudinal impacts of violence and stigma on HIV care continuum and broader health care access among women living with HIV
Learn MoreEnrolling
The role of fatty liver in the epidemic of advanced chronic liver disease among people living with HIV
Learn MoreEnrolling
Drug-drug interaction study between bictegravir/emtricitabine/tenofovir alafenamide and feminizing hormones in trans women living with HIV
Learn MoreOngoing
Optimising Outcomes at Critical Points in the Cascade of HIV Care in Ontario
Learn MoreOngoing
Immunogenicity outcomes in people living with HIV following vaccination for COVID-19 (HIV-COV)
Learn MoreCTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.